Oncology
EGFR-mutant lung cancer: Cracking the drug resistance code
Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade.
News
GSK to file Jemperli for rectal cancer after phase 3 readout
GSK's pivotal AZUR-1 trial of Jemperli monotherapy to delay or eliminate surgery in pre-operative rectal cancer has delivered a positive result.
News
Pay offer rejected as ICR researchers continue strike action
Researchers at the UK Institute of Cancer Research have held historic strikes over pay, claiming they are missing meals and struggling to cover bills.
Oncology
ASCO 2026: All about DNA damage response, with Luke Piggot
Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
News
NICE aims to cut funding for Amgen lung cancer drug Lumykras
Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
